• Markets
  • icon
  • Companies
PIQ · ASX

Proteomics International Laboratories Ltd. (ASX:PIQ)

AU$1.21

 0.02 (1.681%)
ASX:Live
12/04/2024 03:38:52 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

PIQ Overview

PIQ Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Strong

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About PIQ

Website

N/A

Telephone

Address

Description

Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company was founded by Richard Lipscombe and Bill Parker in 2001 and is headquartered in Perth, Australia.

PIQ Price Chart

Key Stats

Market Cap

AU$155.76M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.7 - 1.4

Trade Value (12mth)

AU$33,721.00

1 week

2.54%

1 month

-6.56%

YTD

30.11%

1 year

22.22%

All time high

1.48

Key Fundamentals

EPS 3 yr Growth

165.000%

EBITDA Margin

%

Operating Cashflow

-$6m

Free Cash Flow Return

-96.40%

ROIC

-104.60%

Interest Coverage

N/A

Quick Ratio

7.60

Other Data

Shares on Issue (Fully Dilluted)

122m

HALO Sector

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PIQ Announcements

Latest Announcements

Date Announcements

28 March 24

Investor presentation

×

Investor presentation

25 March 24

Proteomics signs with Oxford Univ to validate test for Endo

×

Proteomics signs with Oxford Univ to validate test for Endo

18 March 24

PromarkerD US commercialisation & Promarker pipeline update

×

PromarkerD US commercialisation & Promarker pipeline update

06 March 24

Proteomics International retains its ISO13485 certification

×

Proteomics International retains its ISO13485 certification

28 February 24

European patent granted for OxiDx technology

×

European patent granted for OxiDx technology

23 February 24

Interim Financial Report and Appendix 4D

×

Interim Financial Report and Appendix 4D

06 February 24

Investor presentation - Euroz Hartleys Healthcare Forum

×

Investor presentation - Euroz Hartleys Healthcare Forum

01 February 24

Study validates biomarkers for oesophageal cancer blood test

×

Study validates biomarkers for oesophageal cancer blood test

01 February 24

Study validates biomarkers for endometriosis blood test

×

Study validates biomarkers for endometriosis blood test

30 January 24

Becoming a substantial holder

×

Becoming a substantial holder

25 January 24

Cleansing prospectus

×

Cleansing prospectus

25 January 24

Proposed issue of securities - PIQ

×

Proposed issue of securities - PIQ

25 January 24

Application for quotation of securities - PIQ

×

Application for quotation of securities - PIQ

25 January 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

25 January 24

Change in substantial holding

×

Change in substantial holding

25 January 24

Investor Presentation

×

Investor Presentation

23 January 24

December 2023 Quarterly Activities Report and Appendix 4C

×

December 2023 Quarterly Activities Report and Appendix 4C

23 January 24

Proposed issue of securities - PIQ

×

Proposed issue of securities - PIQ

23 January 24

Proteomics to raise $6.5m through Institutional Placement

×

Proteomics to raise $6.5m through Institutional Placement

05 January 24

Notification of cessation of securities - PIQ

×

Notification of cessation of securities - PIQ

20 December 23

PromarkerD licence with Omics Global extended to Chile

×

PromarkerD licence with Omics Global extended to Chile

23 November 23

AGM Chairman's Address and Investor Presentation

×

AGM Chairman's Address and Investor Presentation

23 November 23

Results of Meeting

×

Results of Meeting

22 November 23

US Medicare confirms reimbursement price for PromarkerD

×

US Medicare confirms reimbursement price for PromarkerD

13 November 23

Proteomics presents at Bell Potter Healthcare Conference

×

Proteomics presents at Bell Potter Healthcare Conference

PIQ Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.05 -0.05 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.05 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -40.5 -67.6 -12.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.04 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.03 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.1 -85.9 -15.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.6 -3.7 -6.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.07 0.03 0.07 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.07 0.03 0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock 50.6 -55.6 115.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 102 106 116 Lock Lock Lock
Basic m Lock Lock Lock Lock 102 106 116 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -7.9 13.6 -51.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -3 -5 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -36.5 -105.4 -35.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -198.5 -358.9 -993.2 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 299 459 1,093 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -6 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -35.6 -56.7 -22.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -305.2 -421.1 -1,053.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -7 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -32.0 -52.9 -22.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -333.7 -449.1 -1,125.9 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -4 -7 -8 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -5 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -64.0 -73.9 -24.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -218.2 -333.9 -845.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -4 -6 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 6 0 11 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -4 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.5 -52.0 -88.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1.8 -2.5 -9.5 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 6 2 6 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 9 5 10 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -6 -2 -6 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 8 3 8 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 8 3 8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 68.8 -55.4 147.9 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -33.3 -92.2 -61.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -37.6 -146.5 -73.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -71.4 -120.8 -139.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -47.2 -90.4 -104.6 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -36.5 -64.3 -96.4 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -631.4 -2,328.8 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.4 0.3 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -72.7 -62.2 -71.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 9.4 2.6 7.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 9.4 2.6 7.6 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 76.4 48.4 72.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -283.6 -208.0 -516.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.8 0.8 0.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.2 0.6 0.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 10.9 34.7 21.1 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -316.6 -448.9 -1,106.8 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -48.3 -123.9 -80.2 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -33.3 -92.2 -61.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.6 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -37.6 -146.5 -73.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -37.6 -146.5 -73.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 457.7 459.6 1,076.3 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 457.7 459.6 1,076.3 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 15.1 17.6 15.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 442.5 442.0 1,060.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PIQ Shortsell

Frequently Asked Questions

The current share price of Proteomics International Laboratories Ltd. (PIQ:ASX) is AU$1.21.
The 52-week high share price for Proteomics International Laboratories Ltd. (PIQ:ASX) is AU$1.40.
The 52-week low share price for Proteomics International Laboratories Ltd. (PIQ:ASX)? is AU$0.70.
Proteomics International Laboratories Ltd. (PIQ:ASX) does not pay a dividend.
Proteomics International Laboratories Ltd. (PIQ:ASX) does not pay a dividend.
Proteomics International Laboratories Ltd. (PIQ:ASX) has a franking level of 0%.
Proteomics International Laboratories Ltd. (PIQ:ASX) is classified in the Healthcare.
The current P/E ratio for Proteomics International Laboratories Ltd. (PIQ:ASX) is .